Trial Profile
A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs ARCT 021 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Arcturus Therapeutics
- 07 Jul 2022 Status changed from active, no longer recruiting to discontinued.
- 10 May 2021 Results presented in the Arcturus Therapeutics Media Release.
- 10 May 2021 According to an Arcturus Therapeutics media release, the company remains blinded to full trial data. Data from additional endpoints are expected, including neutralizing antibody and T-cell data, during H2 2021